Literature DB >> 26167616

Integrin α4β7 Expression Increases HIV Susceptibility in Activated Cervical CD4+ T Cells by an HIV Attachment-Independent Mechanism.

Jian Ding1, Carley Tasker, Pierre Lespinasse, Jihong Dai, Patricia Fitzgerald-Bocarsly, Wuyuan Lu, Debra Heller, Theresa Li-Yun Chang.   

Abstract

BACKGROUND: CD4 T cells are crucial for the establishment and dissemination of HIV in mucosal tissues during acute infection. Studies indicate that integrin α4β7 CD4 T cells are preferentially infected by HIV in vitro and during acute SIV infection. The integrin α4β7 is thought to promote HIV capture by target cells; however, the role of integrin α4β7 in HIV transmission remains controversial. In this study, we characterized immune phenotypes of human cervical T cells and examined HIV preference in integrin α4β7 CD4 T cells. In vitro all-trans retinoic acid-differentiated peripheral CD4 T cells (atRA-differentiated cells) were included as a comparison.
RESULTS: In both peripheral and cervical cells, the majority of HIV p24 cells were activated CD4 T cells expressing integrin α4β7. Among infected atRA-differentiated cells, the frequency of CCR5 expression was higher in HIV p24 cells than in HIV p24 cells; no such difference was observed in cervical cells. Neither the cyclic hexapeptide CWLDVC nor a monoclonal antibody against integrin α4β7 blocked HIV attachment or gp120 binding to target cells regardless of the presence of CD4, indicating that integrin α4β7 did not facilitate HIV capture by target cells.
CONCLUSIONS: Integrin α4β7 expression increases HIV susceptibility, but the mechanism is not through promoting HIV binding to target cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26167616      PMCID: PMC4503378          DOI: 10.1097/QAI.0000000000000676

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  30 in total

1.  Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection.

Authors:  R S Veazey; K G Mansfield; I C Tham; A C Carville; D E Shvetz; A E Forand; A A Lackner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  17β-estradiol protects primary macrophages against HIV infection through induction of interferon-alpha.

Authors:  Carley Tasker; Jian Ding; Mirco Schmolke; Amariliz Rivera-Medina; Adolfo García-Sastre; Theresa L Chang
Journal:  Viral Immunol       Date:  2014-05-06       Impact factor: 2.257

3.  Preferential and persistent depletion of CCR5+ T-helper lymphocytes with nonlymphoid homing potential despite early treatment of primary HIV infection.

Authors:  R Krzysiek; A Rudent; L Bouchet-Delbos; A Foussat; C Boutillon; A Portier; D Ingrand; D Sereni; P Galanaud; L Grangeot-Keros; D Emilie
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin.

Authors:  Behzad Etemad; Oscar A Gonzalez; Sean McDonough; Victor Pena-Cruz; Manish Sagar
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

5.  The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection.

Authors:  Elena Martinelli; Filippo Veglia; Diana Goode; Natalia Guerra-Perez; Meropi Aravantinou; James Arthos; Michael Piatak; Jeffrey D Lifson; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

6.  Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection.

Authors:  Ronald S Veazey; Preston A Marx; Andrew A Lackner
Journal:  J Infect Dis       Date:  2003-02-24       Impact factor: 5.226

7.  Retinoic acid imprints gut-homing specificity on T cells.

Authors:  Makoto Iwata; Asami Hirakiyama; Yuko Eshima; Hiroyuki Kagechika; Chieko Kato; Si-Young Song
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

8.  CD4 T cell subsets in the mucosa are CD28+Ki-67-HLA-DR-CD69+ but show differential infection based on alpha4beta7 receptor expression during acute SIV infection.

Authors:  M Kader; S Bixler; M Roederer; R Veazey; J J Mattapallil
Journal:  J Med Primatol       Date:  2009-10       Impact factor: 0.667

9.  Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Authors:  Nicholas F Parrish; Craig B Wilen; Lauren B Banks; Shilpa S Iyer; Jennifer M Pfaff; Jesus F Salazar-Gonzalez; Maria G Salazar; Julie M Decker; Erica H Parrish; Anna Berg; Jennifer Hopper; Bhavna Hora; Amit Kumar; Tatenda Mahlokozera; Sally Yuan; Charl Coleman; Marion Vermeulen; Haitao Ding; Christina Ochsenbauer; John C Tilton; Sallie R Permar; John C Kappes; Michael R Betts; Michael P Busch; Feng Gao; David Montefiori; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  PLoS Pathog       Date:  2012-05-31       Impact factor: 6.823

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  15 in total

1.  Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection.

Authors:  Carley Tasker; Amy Davidow; Natalie E Roche; Theresa L Chang
Journal:  Immunohorizons       Date:  2017-11-01

Review 2.  Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.

Authors:  Andrew W Woodham; Joseph G Skeate; Adriana M Sanna; Julia R Taylor; Diane M Da Silva; Paula M Cannon; W Martin Kast
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

3.  Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes.

Authors:  Aida Sivro; Alexandra Schuetz; Daniel Sheward; Vineet Joag; Sergey Yegorov; Lenine J Liebenberg; Nonhlanhla Yende-Zuma; Andrew Stalker; Ruth S Mwatelah; Philippe Selhorst; Nigel Garrett; Natasha Samsunder; Anisha Balgobin; Fatima Nawaz; Claudia Cicala; James Arthos; Anthony S Fauci; Aggrey Omu Anzala; Joshua Kimani; Bernard S Bagaya; Noah Kiwanuka; Carolyn Williamson; Rupert Kaul; Jo-Ann S Passmore; Nittaya Phanuphak; Jintanat Ananworanich; Aftab Ansari; Quarraisha Abdool Karim; Salim S Abdool Karim; Lyle R McKinnon
Journal:  Sci Transl Med       Date:  2018-01-24       Impact factor: 17.956

4.  Ontogeny of CD4+ T Lymphocytes With Phenotypic Susceptibility to HIV-1 During Exclusive and Nonexclusive Breastfeeding in HIV-1-Exposed Ugandan Infants.

Authors:  Elizabeth J McFarland; Tina M Powell; Carolyne Onyango-Makumbi; Weiming Zhang; Kelsey Melander; Prossy Naluyima; Samuel Okurut; Michael A Eller; Mary Glenn Fowler; Edward N Janoff
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

5.  A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques.

Authors:  Anusmita Sahoo; Andrew T Jones; Narayanaiah Cheedarla; Sailaja Gangadhara; Vicky Roy; Tiffany M Styles; Ayalnesh Shiferaw; Korey L Walter; LaTonya D Williams; Xiaoying Shen; Gabriel Ozorowski; Wen-Hsin Lee; Samantha Burton; Lasanajak Yi; Xuezheng Song; Zhaohui S Qin; Cynthia A Derdeyn; Andrew B Ward; John D Clements; Raghavan Varadarajan; Georgia D Tomaras; Pamela A Kozlowski; Galit Alter; Rama Rao Amara
Journal:  Sci Immunol       Date:  2022-07-22

6.  Simian Immunodeficiency Virus Susceptibility, Immunology, and Microbiome in the Female Genital Tract of Adolescent Versus Adult Pigtail Macaques.

Authors:  Alicia R Berard; Charlene Miller; Mariluz Araínga; Courtney Ann Broedlow; Laura Noël-Romas; Luca Schifanella; Tiffany Hensley-McBain; Alex Roederer; Connor B Driscoll; Ernesto Coronado; Jennifer Manuzak; Lyle R McKinnon; Francois Villinger; Thomas J Hope; Adam D Burgener; Nichole R Klatt
Journal:  AIDS Res Hum Retroviruses       Date:  2021-06-22       Impact factor: 1.723

7.  Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway.

Authors:  Fei Liu; Duo Tong; Haoran Li; Mingming Liu; Jiajia Li; Ziliang Wang; Xi Cheng
Journal:  Oncotarget       Date:  2016-02-23

8.  Depot medroxyprogesterone acetate administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa.

Authors:  Carley Tasker; Vanessa Pizutelli; Yungtai Lo; Bharat Ramratnam; Natalie E Roche; Theresa L Chang
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

9.  A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3.

Authors:  Géraldine Arrode-Brusés; Diana Goode; Kyle Kleinbeck; Jolanta Wilk; Ines Frank; Siddappa Byrareddy; James Arthos; Brooke Grasperge; James Blanchard; Thomas Zydowsky; Agegnehu Gettie; Elena Martinelli
Journal:  PLoS Pathog       Date:  2016-06-27       Impact factor: 6.823

10.  Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.

Authors:  Mathieu Uzzan; Minami Tokuyama; Adam K Rosenstein; Costin Tomescu; Ivo N SahBandar; Huaibin M Ko; Louise Leyre; Anupa Chokola; Emma Kaplan-Lewis; Gabriela Rodriguez; Akihiro Seki; Michael J Corley; Judith Aberg; Annalena La Porte; Eun-Young Park; Hideki Ueno; Ioannis Oikonomou; Itai Doron; Iliyan D Iliev; Benjamin K Chen; Jennifer Lui; Timothy W Schacker; Glaucia C Furtado; Sergio A Lira; Jean-Frederic Colombel; Amir Horowitz; Jean K Lim; Nicolas Chomont; Adeeb H Rahman; Luis J Montaner; Lishomwa C Ndhlovu; Saurabh Mehandru
Journal:  Sci Transl Med       Date:  2018-10-03       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.